ArticleScientific reports2026
Magnetic molecularly imprinted polymer coated with chitosan shell for enhanced controlled drug release.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A pH-responsive chitosan-coated magnetic molecularly imprinted polymer (MMIP) was developed as a controlled-release drug carrier with enhanced selectivity, loading capacity, and release modulation. The carrier was constructed by synthesizing Fe3O4@SiO2 magnetic cores and forming a molecularly imprinted shell using 3-aminopropyltriethoxysilane (APTES) as the functional monomer. Imatinib (IMA), a clinically important tyrosine kinase inhibitor, was used as both the model drug and the template to evaluate the carrier’s performance. To further enhance sustained and pH-responsive release, the MMIP was coated with a biocompatible chitosan (CS) layer after drug loading, yielding a hybrid core–shell nanocomposite (MMIP@CS). Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), vibrating sample magnetometry (VSM), microscopic images and dynamic light scattering (DLS) confirmed its structural integrity, magnetic properties, and well-controlled synthesis process. The system exhibited a high drug loading capacity (65.4%), reflecting strong molecular recognition within the imprinted cavities. The release studies at pH 7.4 and 5.5 demonstrated that the CS coating significantly improved release control over 96 h compared to the uncoated MMIP, enabling sustained and pH-dependent drug delivery. Kinetic modeling indicated that the Korsmeyer–Peppas model best described the release mechanism, suggesting a combined diffusion- and polymer-relaxation-controlled process. In vitro cytotoxicity assays further confirmed that IMA-MMIP@CS exhibited enhanced cytotoxicity against K562 cells while maintaining higher viability in normal PBMCs, highlighting its biocompatibility and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.